Related coverage linked through entity extraction aliases.
May 02, 2026
Two studies identify protein recycling dysfunction and transcription factors ZSCAN20/JDP2 as drivers of T-cell exhaustion, with E3 ligases and gene deactivation offering reversal pathways. A third study finds TCF1 insufficient to revert terminally exhausted T cells.
Apr 20, 2026
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Apr 19, 2026
Biopharma companies face a $275b patent cliff as licensing activity shifts toward China. China represented almost half of 2025 licensing activity and contributes about 30% of the global biotech pipeline.
Apr 16, 2026
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
Apr 16, 2026
A new Cochrane review said anti-amyloid Alzheimer’s drugs show no clinically meaningful benefit, but many researchers said the analysis has major limitations. Newer evidence on lecanemab and donanemab and broader drug development efforts continue to shape the field.
Apr 16, 2026
A review of 17 studies involving 20,342 patients found anti-amyloid Alzheimer’s drugs had “trivial” effects after 18 months and increased the risk of brain swelling and bleeding. A separate PET study suggested ARIA-E may mark brain regions with greater amyloid plaque reduction.
Apr 14, 2026
University of Missouri researchers released PSBench, a database of 1.4 million annotated protein structure models verified by independent experts. The resource aims to improve AI assessment of protein models as biologic drug discovery moves toward data-driven design.
Apr 07, 2026
Alzamend Neuro reports pharmacodynamic data showing AL001 may have a distinct brain interaction profile compared to lithium carbonate, with potential tolerability advantages. The Phase II trial analysis suggests AL001 affects key brain metabolites differently while maintaining lithium's core mechanism of action. Further confirmatory studies are planned to validate these initial findings.
Apr 04, 2026
Trump administration cuts to U.S. science funding have raised fears of a brain drain, with thousands of grants cancelled and researchers moving abroad. Experts warned the losses could damage biomedical innovation and the economy.
Apr 02, 2026
A 16-year study links higher vitamin D levels in middle age to lower tau protein deposits in the brain, while a major COVID-19 trial finds vitamin D doesn't reduce acute severity but may help with long COVID recovery. Separate research shows supplementation improves vitamin D levels and stabilizes immune profiles in athletes and non-athletes.
Mar 25, 2026
NICE has upheld appeals to review its guidance on Alzheimer's drugs lecanemab and donanemab, sending the decision back to committee. The manufacturers argued NICE failed to account for the treatments' wider impact on unpaid carers. This comes amid broader challenges in neurodegenerative disease research following recent high-profile clinical trial failures.
Mar 14, 2026
New research demonstrates that blood tests measuring p-tau217 protein can identify dementia risk up to 25 years before symptoms and significantly improve diagnostic accuracy in clinical practice.
Mar 13, 2026
NIH funded dramatically fewer research grants in 2025, with funding rates dropping from 27% to 20% for established investigators and from 26% to 19% for early-career researchers, according to newly released agency data.
Mar 12, 2026
New market research reports analyze biotechnology collaboration agreements from 2020-2026, gas chromatography market growth projections, and Western blotting market trends through 2035.
Mar 09, 2026
Eli Lilly's weight-loss drug Mounjaro fueled sevenfold sales growth in Brazil and doubled sales in India within months of launch, as the company commits $1 billion to make India a global export hub for its supply chain.
Mar 03, 2026
University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
Mar 03, 2026
Researchers are developing gene therapy approaches for neurological disorders and head and neck conditions, using viral vectors and advanced delivery methods to treat brain tumors, Alzheimer's, and Parkinson's disease.
Feb 26, 2026
NeuraLight will present a neuroprogression biomarker that outperforms the current gold standard for tracking Parkinson's disease progression at the AD/PD 2026 conference in Copenhagen beginning March 17.
Feb 21, 2026
Researchers at DZNE and the University of Tübingen have identified neurofilament light chain (NfL) as a blood biomarker detectable across animal species, with levels increasing with age and predicting lifespan in mice.
Feb 24, 2026
AI systems are evolving into essential research collaborators in 2026, while quantum computing emerges as a transformative technology with potential to create $200-500 billion in value for life sciences by 2035.
